Literature DB >> 29680794

Risperidone-associated sinus tachycardia potentiated by paliperidone palmitate in a patient with no prior cardiovascular disease: role of risperidone-related autonomic instability.

Alain Bruno Tagne Nouemssi1.   

Abstract

Risperidone and paliperidone palmitate are two antipsychotic drugs well tolerated in the management of schizophrenia and other psychiatric conditions. There have been few reports of tachycardia induced by either drugs. Here, we report on a 21-year-old man, with a history of schizophrenia, and who developed persistent sinus tachycardia after he was restarted on risperidone, which later worsened after administration of paliperidone palmitate for long-term management. He had no cardiovascular risk factors other than obesity, and a prior well-tolerated risperidone treatment. Clinicians must be aware of the possibility of patients developing sinus tachycardia due to autonomic instability from a prior risperidone treatment, even though overall, these drugs are well tolerated. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  drug interactions; psychiatry (drugs and medicines); schizophrenia

Mesh:

Substances:

Year:  2018        PMID: 29680794      PMCID: PMC5926602          DOI: 10.1136/bcr-2017-221771

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

1.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

Review 2.  A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors.

Authors:  H He; J S Richardson
Journal:  Int Clin Psychopharmacol       Date:  1995-03       Impact factor: 1.659

3.  Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study.

Authors:  Michelle Kramer; Robert Litman; David Hough; Rosanne Lane; Pilar Lim; Yanning Liu; Mariëlle Eerdekens
Journal:  Int J Neuropsychopharmacol       Date:  2009-11-27       Impact factor: 5.176

4.  Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.

Authors:  Michael Davidson; Robin Emsley; Michelle Kramer; Lisa Ford; Guohua Pan; Pilar Lim; Mariëlle Eerdekens
Journal:  Schizophr Res       Date:  2007-04-26       Impact factor: 4.939

5.  Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.

Authors:  Ibrahim Turkoz; Cynthia A Bossie; Jean-Pierre Lindenmayer; Nina Schooler; Carla M Canuso
Journal:  BMC Psychiatry       Date:  2011-02-07       Impact factor: 3.630

6.  Isolated sinus tachycardia following reinitiation of risperidone in a patient with suspected autonomic hypersensitivity.

Authors:  Melanie J Grubisha; Jessica L Brennan; Antoine Douaihy
Journal:  J Pharmacol Pharmacother       Date:  2015 Jan-Mar

7.  Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database.

Authors:  David P J Osborn; Gus Levy; Irwin Nazareth; Irene Petersen; Amir Islam; Michael B King
Journal:  Arch Gen Psychiatry       Date:  2007-02
  7 in total
  1 in total

1.  Tachycardia during Treatment with Risperidone and Paliperidone Palmitate in a Patient without Previous Cardiovascular Disease.

Authors:  Zachary Orlins; Brian Barnett
Journal:  Case Rep Psychiatry       Date:  2021-07-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.